PROFOUND MED CORP PROF 深 沪
等待开盘 12-20 09:30:00 美东时间
7.63
-0.230
-2.93%
华盛通- 最 高7.70
- 今 开7.45
- 成交量 115.11万股
- 最 低 7.22
- 昨 收 7.86
- 总市值 2.29亿
- 52周最高 7.99
- 市盈率 静 --
- 换手率 3.83%
- 52周最低 3.76
- 委 比 -40.60%
- 总股本 3005.31万
- 历史最高 28.97
- 量 比 10.54
- 振 幅 6.11%
- 历史最低 3.10
- 每 手 1
- 风险率 1.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Profound Medical Prices $40M Common Stock Offering
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering and a planned
12-19 21:47
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
Profound Medical Corp. has raised up to $40 million through a registered direct offering and a planned private placement in Canada, with each common share priced at $7.00. The offering, led by healthcare-focused investors and existing shareholders, is expected to close by December 22, 2025, with proceeds to be used for sales and marketing expansion, R&D, strategic transactions, and general corporate purposes. Konik Capital Partners acted as the e...
12-19 13:45
Profound Medical’s TULSA Procedure Gains Recognition at RSNA
Profound Medical ( ($TSE:PRN) ) has issued an announcement. Profound Medical Co...
12-05 06:44
Profound Medical To Launch TULSA-AI Volume Reduction Module For Optimizing Treatment Of Patients With Benign Prostatic Hyperplasia, Or Enlarged Prostate, At RSNA Meeting
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of
11-28 20:47
Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease
Renowned urologist Dr. Mark Hong has achieved a global milestone by performing 200 independent TULSA Procedures using Profound Medical's TULSA-PRO system, revolutionizing MRI-guided prostate therapy. This milestone establishes a new model for incision-free prostate care, demonstrating that urologists alone can safely execute the full procedure, delivering personalized therapy with exceptional precision and preserving patients' quality of life. Th...
11-18 21:15
Profound Medical shares are trading lower. The company reported Q3 financial results.
Profound Medical shares are trading lower. The company reported Q3 financial re...
11-14 05:18
Profound Medical Q3 EPS $(0.26) Beats $(0.36) Estimate, Sales $5.289M Beat $4.995M Estimate
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.36) by 28.77 percent. This is a 31.58 percent increase over losses of $(0.38) per share from
11-14 05:11
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
Profound Medical Regains Exclusive Distribution Rights For TULSA-PRO From Knight Therapeutics In Canada
Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets artificial intelligence ("AI")-powered, MRI-guided,
11-11 05:33
Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026
Profusa has achieved key manufacturing milestones to support 2026 revenue targets for its Lumee tissue oxygen monitoring systems. The company completed its first sensor production run in a new controlled environment room, with capacity exceeding twice the 2026 requirements. It also engaged a contract manufacturer for Lumee patches/readers and pens, with production capacities exceeding demand. Distribution partnerships and clinical collaborations ...
10-28 12:30
